Cardiopulmonary stress testing systems market seen reaching $7.53 billion by 2030

The cardiopulmonary stress testing systems market is projected to grow from $5.75 billion in 2025 to $7.53 billion by 2030 as providers seek better tools for assessing heart and lung function under physical stress. North America led the market in 2025, while rising cardiovascular disease rates and AI-enabled diagnostics are expected to keep demand climbing.

Why it matters: - Cardiopulmonary stress testing systems help clinicians evaluate heart and lung performance during exercise, which supports diagnosis, prognosis and personalized care. - Rising cardiovascular disease prevalence is pushing demand for more precise diagnostic tools. - The market's projected growth signals broader adoption of non-invasive monitoring and exercise testing in routine care.

What happened: - The Business Research Company published a 2026 market report on cardiopulmonary stress testing systems. - The report estimates the market grew from $5.75 billion in 2025 to $6.06 billion in 2026. - The report forecasts the market will reach $7.53 billion by 2030. - The report cites a 5.6% CAGR across the forecast periods. - North America was the largest regional market in 2025.

The details: - Cardiopulmonary stress testing systems measure how the cardiovascular and respiratory systems respond to physical exertion. - The systems are used to customize exercise programs and monitor treatment effectiveness. - The report links market growth to increased cardiovascular disease, wider use of exercise testing in clinical settings, expanded hospital diagnostic capacity and better physiological sensors. - The report also points to rising demand for personalized cardiac evaluations, AI-driven diagnostic analytics, preventive cardiology and wearable health monitoring devices. - Expected trends include broader use of integrated cardiopulmonary exercise testing systems, digital stress ECG platforms, advanced respiratory monitoring tools, data-driven exercise testing protocols and predictive cardiac diagnostics. - The market coverage spans Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report says updated 2026 editions include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics and future trend analysis. - A free sample is available here. - The full report is available here.

Between the lines: - The report frames cardiopulmonary stress testing as part of a shift toward prevention, personalization and data-rich diagnostics. - The inclusion of AI analytics and wearable monitoring suggests the market is moving beyond standalone stress tests toward connected clinical workflows. - The CDC's 2024 figure that cardiovascular disease caused 919,032 deaths in the U.S. in 2023, about one in three deaths, underscores why diagnostic capacity remains a priority.

What's next: - The market is expected to continue expanding through 2030 if cardiovascular disease rates remain elevated and clinical adoption broadens. - Growth will likely depend on how quickly providers adopt integrated CPET systems, digital ECG platforms and predictive analytics tools. - Regional competition may intensify as hospitals and diagnostics providers invest in more advanced exercise testing infrastructure.

The bottom line: - Cardiopulmonary stress testing systems are emerging as a steady-growth diagnostics market, with demand tied to cardiovascular disease burden and the move toward more individualized care.